Artios Pharma closed an oversubscribed $115 million Series D to accelerate its DNA damage response (DDR) portfolio after delivering positive Phase I/IIa signals for lead programs. The financing will advance clinical studies targeting tumor DNA repair vulnerabilities—an approach that has generated approved drugs like PARP inhibitors. Artios said proceeds will support ongoing mid‑stage trials and biomarker development to select responsive patient populations. Investors cited the company’s clinical validation and differentiated DDR targets as rationale for the round.